Where this gets really dicey is the next step: what does it mean for the equity of many of these companies? By and large, nothing good as any increased debt costs all roll down hill, as do risks of lack of refinancing capacity.
That's a great question. Extension fees can be a bump in rate and a nice cash payment, but, in a more distressed situation (e.g., Ayr), a large dollop of stock is the cost. But then again, cannabis stock prices don't seem to care that much about dilution, or much of anything else.
Where this gets really dicey is the next step: what does it mean for the equity of many of these companies? By and large, nothing good as any increased debt costs all roll down hill, as do risks of lack of refinancing capacity.
That's a great question. Extension fees can be a bump in rate and a nice cash payment, but, in a more distressed situation (e.g., Ayr), a large dollop of stock is the cost. But then again, cannabis stock prices don't seem to care that much about dilution, or much of anything else.